التقييم المقارن لنظامي Mispa i2 وIchroma مع اختبار تراص اللاتكس اليدوي لقياس مضاد الستربتوليزين O في المختبرات السريرية

Ahmed, M. K. (2022, December 21). Anti-Streptolysin O (ASO) Test: Principle, Procedure and Interpretation.

[2] Alshawish, F. M. B. M., Abdala, B. A. F., Arqeeq, M. A. M., & Salem, M. O. A. (2025). Phytochemical Profiling screening and Evaluation of Their Multi-target Biological Potentials of Catha edulis Ethanolic Extract. Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 47-53.

[3] Ayoub, E. M., & Wannamaker, L. W. (1962). Evaluation of the streptozyme test for the detection of streptococcal antibodies. Pediatrics, 29(4), 527–535.

[4] Ben Hsin, M. A. M., Emsaed, H. A. M., Abujarida, A. R., Sauf, M. A., Soof, S. A., & Salem, M. O. A. (2025). A Study on the Isolation and Identification of Bacteria in Patients with Urinary Tract Infections in Libyan Laboratories. Afro-Asian Journal of Scientific Research (AAJSR), 1(4), 1-10.

[5] Bhave, C., Kinikar, A., Sani, S., Agarwal, M., & Amdekar, P. C. (1991). Epidemiology of streptococcal infection with reference to rheumatic fever. Indian Pediatrics, 28(12), 1503–1508.

[6] Bisno, A. L., Gerber, M. A., Gwaltney, J. M., Kaplan, E. L., & Schwartz, R. H. (2002). Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clinical Infectious Diseases, 35(2), 113–125.

[7] Boditech Med Inc.’s Technical Services. (2021, July 28). Document No.: INS-AS-EN Revision date: July 28, 2021 (Rev. 07).

[8] Carapetis, J. R., Steer, A. C., Mulholland, E. K., & Weber, M. (2005). The global burden of group A streptococcal diseases. The Lancet Infectious Diseases, 5(11), 685–694.

[9] Centers for Disease Control and Prevention. (n.d.). Group A strep diseases home page and related sites. https://www.cdc.gov/groupastrep/index.html;

[10] E. W. (1932). Antigenic properties of a hemolytic streptococcal toxin associated with hemolysis. Journal of Experimental Medicine, 55(2), 267–280.

[11] Comparison of latex and hemolysin tests for the determination of streptolysin O (ASO) antibody. (1989). Journal of Clinical Pathology, 41(12), 1331–1333.

[12] Efstratiou, A. (2000). Group A streptococci in the 1990s. Journal of Applied Microbiology, 89(s1), 40S–49S.

[13] Efstratiou, A., & Lamani, T. (2016, February 10). Epidemiology of Streptococcus pyogenes. In Streptococcus pyogenes: Basic biology of clinical manifestations. University of Oklahoma Health Sciences Center. PMID: 26866237.

[14] Fernando, M. A., et al. (1990). Anti-streptolysin O titers in a rural population in Ceylon. Journal of Tropical Medicine and Hygiene, 93(2), 112–117.

[15] Gerber, M. A., Shulman, S. T., & Greene, M. (1990). Evaluation of a new latex agglutination test for the detection of streptolysin antibodies. Journal of Clinical Microbiology, 28(6), 1361–1364.

[16] Guilherme, L., Ferreira, F. M., Koller, K. F., Postol, E., & Khalil, G. (2013). A vaccine against Streptococcus pyogenes: Potential for prevention of rheumatic fever and rheumatic heart disease. American Journal of Cardiovascular Medicine, 13(1), 1–4.

[17] Hayney, M., et al. (2018). Antimicrobial resistance in Streptococcus spp. Microbiology Spectrum, 6(2), 1–12.

[18] Kadak, A. E., & Salem, M. O. A. (2020). Antibacterial Activity of Chitosan, Some Plant Seed Extracts and Oils Against Escherichia coli and Staphylococcus aureus. Alinteri Journal of Agriculture Sciences, 35(2), 144–150. doi: 10.47059/alinteri/V35I2/AJAS20086

[19] Khalil, R. A. A., Salem, I. A. S., & Salem, M. O. A. (2025). A Biochemical Study on the Effect of Alcoholic and Aqueous Extracts of Plantago ovata Leaves in Inhibiting the Growth of Antibiotic-Resistant Bacteria. Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 1(2), 38-46.

[20] Klein, G. C. (1974). Manual of Clinical Immunology. American Society for Microbiology.

[21] Lepoutre, A., Doloy, A., Bidet, P., Leblond, A., Perrocheau, A., Bingen, E., et al. (2011). Epidemiology of invasive Streptococcus pyogenes infections in France. Journal of Clinical Microbiology, 49(12), 4094–4100.

[22] Low, D. E. (2016). Nonpneumococcal streptococcal infections and rheumatic fever. In L. Goldman & A. I. Schafer (Eds.), Goldman-Cecil Medicine (25th ed., chap. 290). Elsevier Saunders.

[23] MISPA-i2 Specific Protein Analyzer. (2021, August 22). Technical Review.

[24] Nelson, G. E., Pondo, T., Toews, K., Farley, M. M., Lindegren, M. L., Lynfield, R., Harrison, L. H., Weites, S., Schaffner, W., & Beall, B. (2016). Epidemiology of invasive group A streptococcal infections in the United States, 2005–2012. Clinical Infectious Diseases, 63(4), 478–486.

[25] O'Loughlin, R. E., Roberson, A., Cieslak, P. R., et al. (2007). The epidemiology of invasive group A streptococcal infection and potential vaccine implications, United States, 2000–2004. Clinical Infectious Diseases, 45(7), 853–862.

[26] Public Health Agency of Canada. (2001, September 26). Streptococcus pyogenes - Pathogen Safety Data Sheets. Government of Canada.

[27] Qotbi, A. A., Habib, N. M., & Al, S. E. (2012). Antistreptolysin O titer in health and disease: Levels and significance. Arab, Egypt.

[28] Salem, M. (2024). Antimicrobial Activity of Aqueous Methanolic Extract of Lichen (Usnea barbata) Against Escherichia coli and Staphylococcus aureus. Libyan Journal of Ecological & Environmental Sciences and Technology, 6(01), 19-23.

[29] Salem, M., & Salem, I. (2025). Antimicrobial Polymers: Mechanisms of Action and Applications in Combating Antibiotic Resistance. Al-Imad Journal of Humanities and Applied Sciences (AJHAS), 1(1), 12-15.

[30] Salem, M. O. A., & Alhadad, A. A. (2026). Phytochemical Profiling and In Vitro Antimicrobial Potential of Hypericum decaisneanum Coss. Aerial Parts Endemic to Bani Waleed, Libya. Libyan Open University Journal of Applied Sciences (LOUJAS), 2(1), 97-103.

[31] Salem, M. O. A., Ahmed, G. S., Abuamoud, M. M. M., & Rezgalla, R. Y. M. (2025). Antimicrobial Activity of Extracts of Dandelion (Taraxacum officinale) Against Escherichia coli and Staphylococcus aureus: Mechanisms, Modern Insights, and Therapeutic Potential. Libyan Journal of Medical and Applied Sciences, 3(2), 37-40.

[32] Salem, M. O. A., & Lakwani, M. A. S. (2024). Determination of Chemical Composition and Biological Activity of Flaxseed (Linum usitatissimum) Essential Oil. Journal of Biometry Studies, 4(2), 91-96.

[33] Sen, A., & Ramanan, A. V. (2014). How to use anti-streptolysin O titer. Archives of Disease in Childhood - Education and Practice, 99(6), 231–237.

[34] Soof, S. A., Sauf, M. A., Salim, A. A. A., & Salem, M. O. A. (2025). GC-MS Quantification of Bioactive Isothiocyanates in Sinapis alba Essential Oil and Validation of Rapid Bactericidal Kinetics Against Clinically Relevant Pathogens. Scientific Journal for Publishing in Health Research and Technology, 1(2), 86-93.

[35] Steer, A. C., Lamani, T., Curtis, N., & R., J. (2015). Invasive group A streptococcal disease. Current Pediatrics, 15(3), 120–125.

[36] Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Gerding, D. N., ... & Tunkel, A. R. (2005). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clinical Infectious Diseases, 41(11), 1548–1568.

[37] Still, J. G. (1995). Antistreptolysin O latex test. The Pediatric Infectious Disease Journal, 14(4), S57–S61; Generic Assays. (2014, April 1). Antistreptolysin O Latex - 100 determinations.

[38] Teresa, J., Bogdan, T., Andrula, E., Birgitta, J., et al. (2008). Epidemiology of severe streptococcal disease in Europe. Journal of Clinical Microbiology, 46(7), 2359–2367.

[39] Tsegahun, D., Mehret, T., & Negos, T. (2019). The normal value of the anti-streptolysin O titer in rheumatoid heart disease for patients on secondary prophylaxis and healthy children in Ethiopia. ARC Journal of Cardiology, 5(1), 6–11.